DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Silvant Capital Management LLC

Silvant Capital Management LLC lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 243,587 shares of the medical device company’s stock after selling 36,702 shares during the period. DexCom accounts for 0.7% of Silvant Capital Management LLC’s investment portfolio, making the stock its 24th largest holding. Silvant Capital Management LLC owned 0.06% of DexCom worth $16,330,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Farther Finance Advisors LLC increased its position in DexCom by 79.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,568 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 1,134 shares during the period. Stephens Investment Management Group LLC raised its stake in shares of DexCom by 2.9% during the 3rd quarter. Stephens Investment Management Group LLC now owns 684,485 shares of the medical device company’s stock worth $45,888,000 after buying an additional 19,279 shares in the last quarter. AustralianSuper Pty Ltd increased its holdings in shares of DexCom by 54.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 15,725 shares of the medical device company’s stock valued at $1,054,000 after purchasing an additional 5,568 shares in the last quarter. New York State Teachers Retirement System boosted its position in DexCom by 1.6% during the third quarter. New York State Teachers Retirement System now owns 366,308 shares of the medical device company’s stock worth $24,557,000 after purchasing an additional 5,804 shares in the last quarter. Finally, Avitas Wealth Management LLC increased its position in shares of DexCom by 20.2% in the third quarter. Avitas Wealth Management LLC now owns 6,475 shares of the medical device company’s stock valued at $434,000 after buying an additional 1,086 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 0.2 %

DXCM opened at $70.35 on Friday. The company has a fifty day moving average price of $69.85 and a 200-day moving average price of $95.92. The firm has a market capitalization of $27.48 billion, a P/E ratio of 42.13, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Robert W. Baird upped their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Raymond James dropped their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Barclays reduced their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Finally, Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.